Advances in radiation oncology 2024 Apr 27
Neoadjuvant Cemiplimab Followed by Radiation for Locally Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: A Case Report.
Related Questions
If so, would you modify your radiation dose/field size to account for immunotherapy response? After how many cycles?
New answer by Radiation Oncologist at University of Texas at Tyler (October 27, 2025)
While the definitive trials are yet outstanding and enrollment in NRG HN0014 (NCT06568172) should be encouraged where it is open, the present indications for using cemiplimab ...